Kowalska, K.; Wilczopolski, P.; Buławska, D.; Młynarska, E.; Rysz, J.; Franczyk, B.
The Importance of SGLT-2 Inhibitors as Both the Prevention and the Treatment of Diabetic Cardiomyopathy. Antioxidants 2022, 11, 2500.
https://doi.org/10.3390/antiox11122500
AMA Style
Kowalska K, Wilczopolski P, Buławska D, Młynarska E, Rysz J, Franczyk B.
The Importance of SGLT-2 Inhibitors as Both the Prevention and the Treatment of Diabetic Cardiomyopathy. Antioxidants. 2022; 11(12):2500.
https://doi.org/10.3390/antiox11122500
Chicago/Turabian Style
Kowalska, Klaudia, Piotr Wilczopolski, Dominika Buławska, Ewelina Młynarska, Jacek Rysz, and Beata Franczyk.
2022. "The Importance of SGLT-2 Inhibitors as Both the Prevention and the Treatment of Diabetic Cardiomyopathy" Antioxidants 11, no. 12: 2500.
https://doi.org/10.3390/antiox11122500
APA Style
Kowalska, K., Wilczopolski, P., Buławska, D., Młynarska, E., Rysz, J., & Franczyk, B.
(2022). The Importance of SGLT-2 Inhibitors as Both the Prevention and the Treatment of Diabetic Cardiomyopathy. Antioxidants, 11(12), 2500.
https://doi.org/10.3390/antiox11122500